Holen Sie sich die Stockscreener-App
3.38
1.02%
-0.035
Handel nachbörslich:
3.44
0.06
+1.78%
Turn Therapeutics Inc Aktie (TTRX) Neueste Nachrichten
TTRX: Phase II eczema trial for a novel IL-36/IL-31 inhibitor expects key data in Q2 2026 - TradingView
Turn Therapeutics Talks GX-03 Phase II Eczema Data Timeline and Non-Systemic Topical Strategy - Defense World
TTRX: Lead topical for eczema in phase II, with phase III trials planned and strong safety data - TradingView
Technical Analysis of Turn Therapeutics Inc. (NASDAQ:TTRX) - TradingView
Turn Therapeutics Appoints Robert Redfield as Senior Advisor - TipRanks
Turn appoints Dr. Robert Redfield as senior advisor to guide GX-03 regulatory and clinical strategy - TradingView
Former CDC director joins Turn Therapeutics (TTRX) as senior health policy advisor - Stock Titan
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs - Caledonian Record
How much upside does Compass Therapeutics Inc. haveWall Street Watch & Daily Stock Momentum Reports - mfd.ru
What is the next catalyst for Palvella Therapeutics Inc.July 2025 Spike Watch & Consistent Return Investment Signals - mfd.ru
TTRX Should I Buy - Intellectia AI
Turn Therapeutics Inc.Common Stock (Nasdaq:TTRX) Stock Quote - FinancialContent
Will Ovid Therapeutics Inc. announce a stock splitQuarterly Market Review & Detailed Earnings Play Strategies - mfd.ru
Can Xilio Therapeutics Inc. expand into new marketsDollar Strength & Entry Point Confirmation Signals - mfd.ru
Aug Sentiment: What is the fair value of Candel Therapeutics Inc. stock nowJuly 2025 Reactions & Weekly Top Stock Performers List - mfd.ru
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences - BioSpace
Turn Therapeutics Highlights GX-03 Progress at Investor Conferences - TipRanks
Turn Therapeutics Inc Announces Presentations at Healthcare Conferences - TradingView
Will Turn Therapeutics Turn The Corner In 2026? - RTTNews
Positive Signs As Multiple Insiders Buy Turn Therapeutics Stock - Yahoo Finance
Analyzing Turn Therapeutics (TTRX) & The Competition - Defense World
TTRX Forecast — Price Prediction for 2026. Should I Buy TTRX? - Intellectia AI
When Will Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Turn A Profit? - Yahoo Finance
Turn Therapeutics Advances GX-03 Eczema Trial, Opening a New Catalyst for Investors - TipRanks
Reviewing Turn Therapeutics (TTRX) and Its Peers - Defense World
Turn Therapeutics' (TTRX) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Turn Therapeutics (TTRX) vs. Its Peers Head to Head Survey - Defense World
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Turn Therapeutics advances atopic dermatitis trial, expands pipeline - Investing.com Nigeria
Speculative Buy on Turn Therapeutics: Proprietary Platform, Capital-Efficient Growth, and 2026 Milestones as Key Upside Catalysts - TipRanks
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference - BioSpace
Turn Therapeutics advances atopic dermatitis trial, expands pipeline By Investing.com - Investing.com India
Turn Therapeutics Issues Corporate, Pipeline and Financial Updates - TipRanks
Turn Therapeutics Inc Announces Corporate and Pipeline Updates for 2026 - TradingView — Track All Markets
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44 - Business Wire
Turn Therapeutics Announces Corporate And Pipeline Updates And 2026 Outlook Ahead Of The 44Th Annual J.P. Morgan Healthcare Conference - TradingView
Financial Review: Turn Therapeutics (TTRX) & Its Peers - Defense World
TTRX Forecast — Price Target — Prediction for 2027 - TradingView — Track All Markets
Turn Therapeutics Reaches US$132m Market Cap Benefiting Insider Stock Buying - Sahm
Will Stoke Therapeutics Inc. stock split again soonVolume Spike & Technical Buy Zone Confirmations - ulpravda.ru
Great week for Turn Therapeutics Inc. (NASDAQ:TTRX) insiders who have 59% stake and they haven’t stopped buying - Yahoo Finance
Turn Therapeutics adds McKinsey veteran to board amid M&A focus By Investing.com - Investing.com Nigeria
Los Angeles Daily NewsTurn Therapeutics Inc.Common Stock (Nasdaq:TTRX) Stock Quote - FinancialContent
Turn Therapeutics appoints Martin Dewhurst to its board of directors - marketscreener.com
Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors - TradingView — Track All Markets
Turn Therapeutics appoints veteran executive to board - TipRanks
Turn Therapeutics adds McKinsey veteran to board amid M&A focus - Investing.com
Turn Therapeutics Inc. Appoints Martin Dewhurst to Board of Directors - TradingView — Track All Markets
Turn Therapeutics (TTRX) Stock Analysis Report | Financials & Insights - Benzinga
Ceapro (OTCMKTS:CRPOF) vs. Turn Therapeutics (NASDAQ:TTRX) Head to Head Review - Defense World
Turn Therapeutics (NASDAQ:TTRX) Upgraded at D Boral Capital - Defense World
Turn Therapeutics (NASDAQ:TTRX) Upgraded to "Strong-Buy" at D Boral Capital - MarketBeat
Turn Therapeutics (NASDAQ:TTRX) Now Covered by Analysts at D. Boral Capital - Defense World
3.69%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):